J. V. von Einem

发表

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial)

M. Stauch, A. Crispin, V. Heinemann, 2016, International journal of cancer.

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials

V. Heinemann, C. Westphalen, S. Stintzing, 2020, Journal of Cancer Research and Clinical Oncology.

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

M. Stauch, A. Crispin, V. Heinemann, 2017, Anti-cancer drugs.

Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients

A. Muacevic, C. Fürweger, S. Stintzing, 2020, Cureus.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

W. Scheithauer, V. Heinemann, J. Holch, 2017, European journal of cancer.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

W. Scheithauer, V. Heinemann, J. Holch, 2017, Oncotarget.

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

W. Scheithauer, M. Stauch, V. Heinemann, 2017, International journal of cancer.

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).

V. Heinemann, T. Decker, C. Denzlinger, 2020, European journal of cancer.

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2014, Journal of Cancer Research and Clinical Oncology.

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3)

V. Heinemann, J. Holch, T. Decker, 2021, International journal of cancer.

FIRE-7-Studie (AIO-KRK-0120)

V. Heinemann, J. Holch, J. Pratschke, 2021, Forum.

Non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation. Contrast mixed mode examination vs. only contrast enhanced ultrasound examination.

M. Reiser, B. Wintersperger, K. Nikolaou, 2010, Clinical hemorheology and microcirculation.

In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media

M. Reiser, O. Dietrich, S. Sourbron, 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306

U. Neumann, V. Heinemann, D. Seehofer, 2020, Annals of Surgical Oncology.

Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.

M. Reiser, O. Dietrich, S. Sourbron, 2012, AJR. American journal of roentgenology.

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

V. Heinemann, T. Decker, A. Tannapfel, 2022, Cancers.

Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer

V. Heinemann, J. Holch, M. Michl, 2017, Visceral Medicine.

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.

W. Scheithauer, V. Heinemann, T. Decker, 2020, European journal of cancer.

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial

V. Heinemann, P. Nelson, R. Huss, 2015, BMC Cancer.

Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome

M. Flaig, M. Reincke, C. Then, 2012, Oncology Research and Treatment.

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.

U. Keilholz, S. Stintzing, H. Osumi, 2021, European journal of cancer.

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

W. Scheithauer, V. Heinemann, J. Holch, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial

V. Heinemann, H. Volk, J. Holch, 2019, International journal of cancer.

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

V. Heinemann, H. Volk, J. Holch, 2017, Oncotarget.

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

V. Heinemann, T. Decker, C. Denzlinger, 2022, Frontiers in Oncology.

Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259].

W. Scheithauer, V. Heinemann, T. Decker, 2022, European journal of cancer.

Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases

A. Haidenberger, S. Stintzing, Michael Fedorov, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

V. Heinemann, S. Stintzing, A. Schalhorn, 2014, Anti-cancer drugs.

Dynamic Contrast-Enhanced Computed Tomography Imaging Biomarkers Correlated With Immunohistochemistry for Monitoring the Effects of Sorafenib on Experimental Prostate Carcinomas

Konstantin Nikolaou, Olaf Dietrich, Michael Ingrisch, 2012, Investigative radiology.

Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial

W. Scheithauer, V. Heinemann, J. Holch, 2018, International journal of cancer.

Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study

W. Scheithauer, V. Heinemann, J. Holch, 2020, Anti-cancer drugs.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, V. Heinemann, J. Holch, 2019, European journal of cancer.

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

V. Heinemann, H. Volk, J. Holch, 2017, Oncotarget.

Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases

A. Haidenberger, S. Stintzing, Michael Fedorov, 2018, Cancer research and treatment : official journal of Korean Cancer Association.